In this study, we found that patients with LUAD in the high-risk group showed a higher tumor mutation burden and higher mutation frequencies of TP53, TTN, MUC16, and COL5A2 than patients in the low-risk group. The gene discussed is COL5A2; the disease is neoplasm.